Stock·NYSE·Financial Services
Chubb Limited (CB)
- Market cap
- $138.80B
- P/E
- 12.35
- Dividend yield
- 1.11%
- Street target
- $365.00median of 25 analysts
- 52-week range
- $266.40 $365.91
The short version
Where CB stands today, in four lines, and what CleaRank Financial AI makes of it.
CB at a glance
Chubb Limited (CB): Hold, 57/100 on CleaRank's AI score.
- Trend Up: the price is above both its 50- and 200-day moving averages ($340.60 and $331.51).
- Earnings CB beat estimates in 5 of its last 5 quarters, yet fell the next day after 3 of those beats.
- Insiders Insiders sold $89.6M and bought $3.0M over the last 18 months.
- Valuation P/E of 12.4 against 16.5 for the Financial Services sector: a discount to peers (-25%).
Figures as of October 16, 2026.
CleaRank Financial AI
Chubb Limited (CB) is currently trading at $359.77, a level that aligns closely with its analyst median target price of $365.00, indicating limited immediate upside potential.
The company operates within the Financial Services sector, specifically in Property & Casualty Insurance, and has demonstrated a revenue growth of 6.1%. Despite a 'Hold' consensus from Wall Street analysts, the stock's technical indicators suggest it is approaching overbought territory, with the 14-day RSI at 72.92. Fundamentally, Chubb exhibits strong profitability with a net profit margin of 18.07% and a return on equity of 14.82%, both exceeding sector medians. However, a significant volume of insider selling, totaling $89.6 million against only $3 million in purchases, presents a notable concern. This heavy selling pressure, as indicated by the heavy insider selling, warrants caution despite the company's strong financial health and positive growth trajectory.
Only on CleaRank
Figures we compute ourselves from CB's own price, earnings and insider-filing history. Tap one to see it in context.
Price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
4/4Price above its 50-day average ›
The price of $359.77 is 5.6% above the 50-day simple moving average of $340.60.Price above its 200-day average ›
The price is 8.5% above the 200-day simple moving average of $331.51.50-day average above the 200-day ›
The 50-day average ($340.60) is 2.7% above the 200-day average ($331.51), the arrangement of a rising longer-term trend.In the upper half of its 52-week range ›
The price sits at 94% of its 52-week range, between $266.40 and $365.91.
CB share price
Pick a period: each tab shows how far CB has moved over it, to the last close.
Today's trading
Where CB sits inside today's range and its 52-week range.
Fundamentals
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
5/5P/E below the sector median ›
The trailing P/E of 12.35 is 25.1% below the Financial Services median of 16.5.P/S below the sector median ›
The price-to-sales ratio of 2.20 is 42.1% below the sector median of 3.8.Profitable over the last 12 months ›
Net income over the last 12 months was $11.2B on revenue of $61.9B, a net margin of 18.1%.Beat estimates in most recent reports ›
CB beat the EPS estimate in 5 of its last 5 reports.Pays a dividend ›
The trailing dividend yield is 1.11%, or $3.98 a share a year.
Key statistics
The headline figures for CB.
As of October 16, 2026, CB trades at $359.77, with a market value of $138.80B, a P/E ratio of 12.35 and a dividend yield of 1.11%.
What the numbers say
CleaRank Financial AI's reading of CB's valuation, growth and risks.
Chubb Limited's valuation appears reasonable, with a P/E ratio of 12.35, which is below the sector median of 16.5, and a Price-to-Sales ratio of 2.20, also below the sector median of 3.8.
The company's return on equity stands at 14.82%, surpassing the sector average of 13.8%, and its profit margin is a strong 18.07%, well above the sector average. Despite these favorable fundamental metrics, the significant insider selling activity is a key concern that tempers the bullish outlook. While the company's debt-to-equity ratio of 0.31 is in line with the sector average, the heavy disposition of shares by insiders suggests potential headwinds or a lack of conviction from management regarding near-term price appreciation.
CB against the Financial Services sector
How CB compares with the median Financial Services stock CleaRank tracks.
Price to earnings vs sector: CB trades at a notable discount to sector peers (-25%), which may indicate undervaluation or specific company headwinds.
Return vs IAI: Since May 6, 2025, CB has gained 24.5% against a gain of 23.4% for IAI.
Performance against IAI
CB and the Financial Services sector fund over the same days.
Revenue and earnings
How much CB sells, and how much of it becomes profit.
Revenue growth: Revenue grew 6.5% in FY2025 to $59.8B, from $56.2B a year earlier.
Profit margin: The net margin was 17.8% in FY2025, up from 17.2% the year before.
Profitable: CB earned $10.6B in FY2025.
Earnings reality check
Did CB beat what analysts expected, and how did the stock react?
Earnings record: CB beat the analyst estimate in 5 of the last 5 quarters.
Market reaction: The stock fell in the first session after 3 of those 5 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Oct 21, 2025after close | $6.16 | $7.49 | +21.59% | +2.70% | +2.35% |
| Jul 22, 2025after close | $5.97 | $6.14 | +2.85% | -3.08% | -3.65% |
| Apr 22, 2025after close | $3.23 | $3.68 | +13.93% | -2.04% | -1.88% |
| Jan 28, 2025after close | $5.45 | $6.02 | +10.46% | +1.31% | -0.01% |
| Oct 29, 2024after close | $4.99 | $5.72 | +14.63% | -1.24% | -3.45% |
Reports after October 21, 2025 are not yet in our data.
As of October 16, 2026, CB has beaten the analyst EPS estimate in 5 of its last 5 reported quarters and fell in the first trading session after 3 of those beats; its most recent report in our data, on October 21, 2025, came in 21.59% above the estimate and the stock moved +2.70% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
AI analysis and technicals
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
2/3RSI not overbought or oversold ›
The 14-day RSI is 72.9, in overbought territory.RSI above 50 ›
An RSI of 72.9 is above the 50 midpoint, so buyers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is positive, so the 12-day average is above the 26-day average.
CleaRank AI analysis of CB
The score, the reasoning behind it, and what could move the price next.
Chubb Limited's stock is currently trading above its 50-day and 200-day moving averages ($340.60 and $331.51), at $340.60 and $331.51 respectively, and also above its 20-day exponential moving average at $342.29.
The 14-day Relative Strength Index (RSI) is at 72.92, signaling that the stock is in overbought territory and may be due for a pullback. The Moving Average Convergence Divergence (MACD) is at 3.498, indicating positive momentum, but the high RSI suggests that further upward movement could be limited in the short term. Key resistance may be found near recent highs, while support levels are indicated by the moving averages.
Consistent EPS Beat History ›
Chubb Limited has a strong track record of exceeding analyst EPS estimates, most recently by over 21%, which could provide underlying support for the stock.
Source: Earnings ReportsAnalyst Price Targets Near Current Price ›
The median analyst price target of $365.00 offers only 1.5% upside from the current price of $359.77, suggesting limited immediate catalyst for price appreciation from analyst expectations.
Source: Wall Street Summary
Heavy Insider Selling Continues ›
Insiders have sold $89.6 million worth of shares against only $3 million in purchases, indicating a strong net selling trend that could pressure the stock price.
Source: Insider Transaction DataOverbought Technical Conditions ›
The 14-day RSI is at 72.92, signaling that the stock is overbought and may be due for a short-term correction or consolidation.
Source: Technical Analysis
- Given the stock is trading near its 50-day and 200-day SMAs and is currently overbought (RSI 72.92), consider waiting for a pullback to a more favorable entry point.
Technical indicators
Momentum and trend for CB, from its daily closes.
As of October 16, 2026, with CB at $359.77, its 14-day RSI is 72.9 (overbought territory), its 50-day simple moving average is $340.60 and its 200-day is $331.51.
Calculated by CleaRank on daily closes as of October 16, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26).
What CB moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 16, 2026, CB's 1-year correlation of daily returns is +0.09 with S&P 500 (SPY), -0.10 with Nasdaq 100 (QQQ), -0.15 with Bitcoin (BTC) and -0.04 with gold (XAU).
What Wall Street expects
The analysts' target range and how their ratings split.
Analysts checks
1/3Most analysts rate it a buy ›
9 of 25 analysts rate it a buy or strong buy, 14 a hold and 2 a sell.Median target above the price ›
The median 12-month target of $365.00 is 1.5% above the price.More buy ratings than three months ago ›
9 of 25 rate it a buy now, against 9 of 25 three months ago.
CB Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 9, 2026 | JP Morgan | Maintains | Neutral |
| Oct 7, 2026 | Mizuho | Maintains | Neutral |
| Oct 7, 2026 | Cantor Fitzgerald | Maintains | Neutral |
| Oct 6, 2026 | Morgan Stanley | Maintains | Equal-Weight |
| Sep 16, 2026 | Mizuho | Maintains | Neutral |
| Aug 19, 2026 | Morgan Stanley | Maintains | Equal-Weight |
As of October 16, 2026, 25 Wall Street analysts cover CB: 9 rate it a buy or strong buy, 14 a hold and 2 a sell or strong sell. Their 12-month price targets range from $307.00 to $425.00, with a median of $365.00, 1.5% above the price of $359.77.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
A trade plan, if you want one
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
CB trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Entry Strategies pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from CB's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much CB tends to move, against the market and on its own.
The long record
CB's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
3/4Average daily move under 2% ›
The price has moved 0.99% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 40.0%, from February 2020 to March 2020, regained by February 2021.Most 1-year holds ended higher ›
77% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $33,311, against $42,525 in the S&P 500 (SPY).
CB Drawdowns & Recovery
As of October 16, 2026, CB's worst peak-to-trough fall over the last 10 years with dividends reinvested was -40.0% (February 2020 to March 2020); it regained that peak by February 2021, 11 months after the low, and 77% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into CB in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: CB trailed the S&P 500 over this period: $33,311 against $42,525.
A $10,000 investment in CB in October 2016 would be worth about $33,311 today with dividends reinvested, compared with about $42,525 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to CB, and which have not.
Strongest month, November: an average of +4.19%, up in 7 of 10 years.
Weakest month, March: an average of -3.65%, up in 4 of 10 years.
This month, October: has averaged +3.69%, up in 6 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, CB's strongest calendar month has been November (average +4.19%, up in 7 of 10 years) and its weakest March (average -3.65%, up in 4 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
Long-term scenarios
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in CB, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in CB today could grow to about $21,685 by 2036 in the base case, with a 90th-percentile outcome near $57,357 and a 10th-percentile outcome around $8,198. The simulation models price only; at today's 1.11% yield, dividends would add to these figures. Projections are statistical simulations, not guarantees.
CB Stock Price Prediction: 2030
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $490 for CB by 2030 in the base case, from $360 today (1.4x over 4 years). The 10th-percentile path ends near $265. These are outcomes of a Monte Carlo simulation run on CB's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $286 | $389 | $529 | |
| 2028 | $272 | $420 | $649 | |
| 2029 | $266 | $454 | $773 | |
| 2030 | $265 | $490 | $907 | |
| 2031 | $266 | $530 | $1,054 |
Method: a lognormal simulation of CB's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles.
Insider trading
What the people running the company have bought and sold.
CB insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Insider buying: Insiders bought $3.0M on the open market and sold $89.6M.
As of October 16, 2026, CB insiders reported 25 open-market sales worth $89.6M and 2 open-market purchases worth $3.0M over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Aug 21, 2026 | Michael P Connors
Director
|
Sell | 5.5K | $1.9M |
| Jul 28, 2026 | Joseph F Wayland
General Counsel
|
Sell | 8.5K | $3.1M |
| Jun 8, 2026 | Juan Luis Ortega
Officer
|
Sell | 3.9K | $1.3M |
| Jun 8, 2026 | Juan Luis Ortega
Officer
|
Option | 3.9K | $540.2K |
| May 28, 2026 | John W Keogh
President
|
Grant | 62.4K | - |
| May 27, 2026 | John W Keogh
President
|
Sell | 23.0K | $7.4M |
| May 21, 2026 | Michael G Atieh
Director
|
Sell | 578 | $190.5K |
| May 21, 2026 | Michael G Atieh
Director
|
Grant | 681 | - |
| May 21, 2026 | Nancy Buese
Director
|
Grant | 1.1K | - |
| May 21, 2026 | Nelson J Chai
Director
|
Grant | 681 | - |
| May 21, 2026 | Michael P Connors
Director
|
Grant | 681 | - |
| May 21, 2026 | Michael L Corbat
Director
|
Grant | 681 | - |
| May 21, 2026 | Fred Zuliu Hu
Director
|
Grant | 1.1K | - |
| May 21, 2026 | Robert J Hugin
Director
|
Grant | 1.1K | - |
| May 21, 2026 | Robert W Scully
Director
|
Grant | 1.3K | - |
| May 21, 2026 | Theodore E Shasta
Director
|
Grant | 681 | - |
| May 21, 2026 | David H Sidwell
Director
|
Grant | 757 | - |
| May 21, 2026 | Olivier Steimer
Director
|
Grant | 681 | - |
| May 21, 2026 | Frances Fragos J.d. Townsend
Director
|
Grant | 681 | - |
| Mar 19, 2026 | Olivier Steimer
Director
|
Sell | 2.0K | $658.6K |
| Mar 6, 2026 | George F Ohsiek
Officer
|
Sell | 770 | $250.4K |
| Mar 4, 2026 | Bryce L Johns
Officer
|
Sell | 1.5K | $504.9K |
| Mar 3, 2026 | Joseph F Wayland
General Counsel
|
Sell | 7.6K | $2.6M |
| Mar 2, 2026 | Peter C Enns
Chief Financial Officer
|
Grant | 5.4K | - |
| Mar 2, 2026 | Evan G Greenberg
Chief Executive Officer
|
Grant | 49.9K | - |
| Mar 2, 2026 | Bryce L Johns
Officer
|
Grant | 4.3K | - |
| Mar 2, 2026 | John W Keogh
President
|
Grant | 14.4K | - |
| Mar 2, 2026 | Paul Mcnamee
Officer
|
Grant | 1.2K | - |
| Mar 2, 2026 | Frances D O'Brien
Officer
|
Grant | 1.1K | - |
| Mar 2, 2026 | George F Ohsiek
Officer
|
Grant | 1.2K | - |
| Mar 2, 2026 | Juan Luis Ortega
Officer
|
Grant | 904 | - |
| Mar 2, 2026 | Joseph F Wayland
General Counsel
|
Grant | 3.5K | - |
| Feb 13, 2026 | George F Ohsiek
Officer
|
Sell | 5.1K | $1.7M |
| Feb 12, 2026 | Evan G Greenberg
Chief Executive Officer
|
Sell | 14.9K | $5.0M |
| Feb 12, 2026 | George F Ohsiek
Officer
|
Option | 2.1K | $250.0K |
| Feb 6, 2026 | Timothy Alan Boroughs
Chief Investment Officer
|
Sell | 27.8K | $9.2M |
| Feb 6, 2026 | Timothy Alan Boroughs
Chief Investment Officer
|
Option | 27.8K | $3.8M |
| Feb 5, 2026 | Evan G Greenberg
Chief Executive Officer
|
Sell | 15.1K | $5.0M |
| Dec 15, 2025 | Evan G Greenberg
Chief Executive Officer
|
Option | 844 | $99.9K |
| Dec 2, 2025 | Juan Luis Ortega
Officer
|
Sell | 4.4K | $1.3M |
| Dec 2, 2025 | Juan Luis Ortega
Officer
|
Sell | 864 | $253.7K |
| Nov 24, 2025 | Timothy Alan Boroughs
Chief Investment Officer
|
Sell | 11.4K | $3.4M |
| Nov 24, 2025 | Timothy Alan Boroughs
Chief Investment Officer
|
Grant | 850 | - |
| Nov 18, 2025 | Evan G Greenberg
Chief Executive Officer
|
Grant | 3.3K | - |
| Nov 14, 2025 | John J Lupica
Officer
|
Sell | 16.4K | $4.9M |
| Nov 13, 2025 | Joseph F Wayland
General Counsel
|
Sell | 5.8K | $1.7M |
| Oct 27, 2025 | John J Lupica
Officer
|
Sell | 23.7K | $6.7M |
| Oct 27, 2025 | John J Lupica
Officer
|
Option | 23.7K | $2.8M |
| Jul 25, 2025 | Michael L Corbat
Director
|
Buy | 425 | $114.7K |
| Jul 1, 2025 | John J Lupica
Officer
|
Sell | 5.5K | $1.6M |
| Jul 1, 2025 | John J Lupica
Officer
|
Option | 2.9K | $344.2K |
| Jun 20, 2025 | John W Keogh
President
|
Grant | 1.1K | - |
| Jun 16, 2025 | Michael G Atieh
Director
|
Sell | 538 | $154.7K |
| Jun 6, 2025 | John W Keogh
President
|
Sell | 9.8K | $2.9M |
| Jun 6, 2025 | John W Keogh
President
|
Buy | 9.8K | $2.9M |
| Jun 4, 2025 | Joseph F Wayland
General Counsel
|
Sell | 5.3K | $1.5M |
| May 21, 2025 | John W Keogh
President
|
Sell | 85.1K | $24.7M |
| May 21, 2025 | John W Keogh
President
|
Option | 65.9K | $8.4M |
| May 20, 2025 | Juan Luis Ortega
Officer
|
Sell | 6.5K | $1.9M |
| May 20, 2025 | Juan Luis Ortega
Officer
|
Option | 6.5K | $770.0K |
| May 15, 2025 | Michael G Atieh
Director
|
Grant | 771 | - |
| May 15, 2025 | Nancy K. Buese
Director
|
Grant | 1.3K | - |
| May 15, 2025 | Sheila P Burke
Director
|
Grant | 771 | - |
| May 15, 2025 | Nelson J Chai
Director
|
Grant | 771 | - |
| May 15, 2025 | Michael P Connors
Director
|
Grant | 771 | - |
| May 15, 2025 | Michael L Corbat
Director
|
Grant | 771 | - |
| May 15, 2025 | Fred Zuliu Hu
Director
|
Grant | 771 | - |
| May 15, 2025 | Robert J Hugin
Director
|
Grant | 1.3K | - |
| May 15, 2025 | Robert W Scully
Director
|
Grant | 1.4K | - |
| May 15, 2025 | Theodore E Shasta
Director
|
Grant | 771 | - |
| May 15, 2025 | David H Sidwell
Director
|
Grant | 771 | - |
| May 15, 2025 | Olivier Steimer
Director
|
Grant | 771 | - |
| May 15, 2025 | Frances Fragos J.d. Townsend
Director
|
Grant | 771 | - |
Source: TwelveData, from reported insider filings
Questions people ask
Answered from the figures on this page, as of October 16, 2026.